A carregar...
Doravirine Exposure and HIV-1 Suppression after Switching from an Efavirenz-Based Regimen to Doravirine-Lamivudine-Tenofovir Disoproxil Fumarate
Doravirine is a nonnucleoside reverse transcriptase inhibitor that has been approved for the treatment of HIV-1. In a phase 1 trial, doravirine exposure was transiently decreased when treatment was started immediately after the cessation of efavirenz treatment. In a post hoc subgroup analysis of par...
Na minha lista:
| Publicado no: | Antimicrob Agents Chemother |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society for Microbiology
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6879224/ https://ncbi.nlm.nih.gov/pubmed/31548188 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01298-19 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|